Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging (ACCRUE)

• ClinicalTrials.gov Identifier: NCT03052166
• Recruitment Status: Completed
• First Posted: February 14, 2017
• Last Update Posted: March 18, 2021
• Sponsor: QT Ultrasound LLC
• Information provided by (Responsible Party): QT Ultrasound LLC

Study Description

Brief Summary:

Brief Summary: The QT Ultrasound system is an automated scanner which transmits pulsed ultrasound plane waves through the breast, as well as collects reflected ultrasound output. As the patient lays prone on a table, the breast is submerged in a warm water bath. The transmitter and receiver assembly moves around the suspended breast to record data for successive sub-volumes of targeted tissue. More than 2000 elements in the curvilinear transducer's array encircle the breast to gather data from the tissue structures of the breast, from nipple to chest wall. Information gathered from this automated QT scan encompasses the entire breast which is currently not commercially available using any other ultrasound technology.

Condition or disease	Intervention/treatment
Breast	Device: QT Ultrasound scan

Detailed Description:

This is a prospective, multicenter, multi-arm case collection study, with IRB approval. The study will follow an adaptive design with an initially planned total enrollment of approximately 600 cases to include both benign and malignant cases, representative of all tissue densities.

The images and clinical data accrued in this prospective case collection will be used for creation of a database to facilitate future reader's studies, publications, building teaching files, and future marketing for QT Ultrasound.

Study Design

• Study Type: Observational
• Actual Enrollment: 755 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: A Prospective Multi-center Case Collection Study of Breast Imaging Examinations From Women to Evaluate the Non-inferiority of QT Ultrasound Compared to Digital Mammography-Digital Breast Tomography (DM-DBT)
• Actual Study Start Date: April 18, 2017
• Actual Primary Completion Date: December 31, 2019
• Actual Study Completion Date: January 1, 2020

Groups and Cohorts

Group/Cohort	Intervention/treatment
Cohort A; The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.	Device: QT Ultrasound scan; QT Ultrasound scan
Cohort B; The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.	Device: QT Ultrasound scan; QT Ultrasound scan
Cohort C; The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.	Device: QT Ultrasound scan; QT Ultrasound scan

Outcome Measures

Primary Outcome Measures :

1. Comparison of QT Ultrasound to DM-DBT [ Time Frame: 12 months ]
   Non-inferiority evaluation of sensitivity, specificity, positive predictive value and non-cancer recall rate.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Sampling Method: Probability Sample

Study Population

Women, age 18 and older

Criteria

INCLUSION CRITERIA All Subjects

1. Female
2. Age 18 or older
3. Willing to receive a QT Ultrasound Breast Scan
4. Willing and able to provide written Informed Consent prior to any research-related procedure(s)

Cohort A and B Subjects that do not meet these Inclusion Criteria will be evaluated for Inclusion in Cohort C

1. Eligible for routine screening mammography as per ACR guidelines
2. Willing and able to submit or complete at the clinical site a Digital Mammography with Digital Breast Tomosynthesis exam (to include Craniocaudal (CC) and Mediolateral Oblique (MLO) views - for one or both breasts, within 3 months, before or after, their QT scan.

Cohort C

1. Willing and able to submit available breast imaging - for one or both breasts, before or after, their QT scan.

EXCLUSION CRITERIA All Subjects

1. Pregnancy
2. Currently breastfeeding
3. Allergies to device materials
4. Physical inability to tolerate the procedure on the scanner, i.e. inability to lie prone and still for up to 30 minutes at a time
5. Open wounds, sores or skin rash present on the breast(s) or nipple discharge from the scanned breast
6. Breasts too large for scanner, i.e. inability to successfully "fit" breast after the subject is placed on scanner
7. Body weight greater than 400 lbs. (180 kg)
8. Has a concurrent disease or condition which in the judgment of the Principal Investigator disqualifies the subject, from participating in the study
9. Magnetic material in the chest which in the judgement of the Principal Investigator would interfere with or be impacted by the magnets within the study device.

Cohort A and B Subjects that meet any of these conditions below will not be eligible for Cohort A or B and will be evaluated for eligibility in Cohort C.

1. History of breast cancer in the past 12 months.
2. Most recent screening mammography exam was completed more than 3 months but less than 11 months prior.
3. History of breast surgeries or interventional breast procedures in the past 12 months, except for Fine Needle Aspiration(s) or Cyst Aspiration(s)

Contacts and Locations

Locations

United States, California

Memorial Care Long Beach

Long Beach, California, United States, 90806

Marin Breast Health Trial Center

Novato, California, United States, 94949

Sponsors and Collaborators

QT Ultrasound LLC

More Information

• Responsible Party: QT Ultrasound LLC
• ClinicalTrials.gov Identifier: NCT03052166
• Other Study ID Numbers: BR005
• First Posted: February 14, 2017
• Last Update Posted: March 18, 2021
• Last Verified: March 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No